• 作者：F. Catalá ; -Ló ; pez^a ; ^b ; ^{ferran_catala@hotmail.com} ; A. Garcí ; a-Alté ; s^a ; ^c ; E. Á ; lvarez-Martí ; n^d ; R. Gè ; nova-Maleras^e ; C. Morant-Ginestar^f ; E. Arana^a ; ^g
• 关键词：Evaluació ; n econó ; mica ; Coste-efectividad ; Cá ; ncer ; Oncolog&iacute ; a ; Tumores malignos ; Farmacoeconom&iacute ; a ; Españ ; a
• 刊名：Farmacia Hospitalaria
• 出版年：2012
• 期刊代码：pca388_11306343
• 类别：pha
• 出版时间：May-June, 2012
• 卷：36
• 期：3
• 页码：141-147
• 文件大小：197 K

Objective

To review standard methods used to evaluate the efficiency of oncology interventions, comparing their main characteristics with those of the studies aimed for other conditions.

Methods

We performed a systematic review and comparative analysis calculating odds ratios (OR). We searched the biomedical literature to assess economic evaluation studies on malignant neoplasms in Spain published between 1983 and 2008. Their characteristics were reviewed and summarised, including the following variables: journal and year of publication, intervention, type and design of study, perspective, type of costs, financing source, and decision-making recommendations.

Results

Sixty-three studies were included. Main characteristics of the reports were: cost-effectiveness analysis and therapeutic interventions (60.3%; n = 38). Seventeen studies (27.0%) used an observational design. Economic evaluations of malignant neoplasms showed the following associations (compared to those studies addressing other causes [n = 411]): cost minimisation analysis (OR: 1.73; 95%confidence interval [CI]: 0.91-3.27), diagnostic interventions (OR: 2.18; 95%CI: 1.07-4.43), decision analysis design (OR: 0.46; 95%CI: 0.24-0.87), societal perspective (OR: 0.20; 95%CI: 0.05-0.86) and for-profit source of financing (OR: 0.52; 95%CI: 0.30-0.93).

Conclusions

Economic evaluations of interventions for malignant neoplasms are not common despite the gradual increase produced during recent years in Spain. Reports presented heterogeneity in the quality of the information regarding the methods and the data sources used. Further efficiency evaluations of oncology interventions are needed and methodological quality should be warranted.